Cantor Fitzgerald Reiterates Neutral on Madrigal Pharmaceuticals
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Prakhar Agrawal has reiterated a Neutral rating on Madrigal Pharmaceuticals (NASDAQ:MDGL).
October 11, 2024 | 5:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating for Madrigal Pharmaceuticals, indicating no change in their outlook for the company.
The reiteration of a Neutral rating by Cantor Fitzgerald suggests that the analyst sees no immediate catalysts for significant price movement in Madrigal Pharmaceuticals. This rating indicates a hold position, reflecting a balanced view of potential risks and rewards.
CONFIDENCE 100
IMPORTANCE 50
RELEVANCE 100